Lib Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults With Elevated Ldl-Cholesterol
Lib Therapeutics 向 FDA 提交了針對成年人高LDL-膽固醇治療的 Lerodalcibep 生物製劑許可申請。
Lib Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults With Elevated Ldl-Cholesterol
Lib Therapeutics 向 FDA 提交了針對成年人高LDL-膽固醇治療的 Lerodalcibep 生物製劑許可申請。
使用瀏覽器的分享功能,分享給你的好友吧